| Literature DB >> 29243351 |
Kei-Long Cheung1, Ben F M Wijnen1,2, Mickaël Hiligsmann1, Kathryn Coyle3, Doug Coyle4,3, Subhash Pokhrel3, Hein de Vries5, Maximilian Präger6, Silvia M A A Evers1,7.
Abstract
BACKGROUND AND AIM: The cost-effectiveness of internet-based smoking cessation interventions is difficult to determine when they are provided as a complement to current smoking cessation services. The aim of this study was to evaluate the cost-effectiveness of such an alternate package compared with existing smoking cessation services alone (current package).Entities:
Keywords: EQUIPTMOD; Economic evaluation; internet-based; model; smoking cessation; tobacco
Mesh:
Year: 2017 PMID: 29243351 PMCID: PMC6032907 DOI: 10.1111/add.14069
Source DB: PubMed Journal: Addiction ISSN: 0965-2140 Impact factor: 6.526
Figure 1Forest plot of the meta‐analysis. Relative risk (RR) and its 95% confidence interval (CI)
Costs, effects and reach of the interventions in current package.
| Interventions | Costs per smoker per intervention (€) | Effect | Reach as % of smokers |
|---|---|---|---|
| Top‐level interventions | |||
| Brief physician advice | 33.00 [62] | 1.40 [63] | 21.00 |
| Pharmaceutical interventions | |||
| Rx mono nicotine Replacement (NRT) | 225.05 [64] | 1.60 [65] | 5.00 |
| Rx combo nicotine Replacement (NRT) | 465.24 [64] | 2.14 [65] | 2.00 |
| Varenicline (standard duration) | 325.71 [64] | 2.30 [66] | 5.00 |
| Varenicline (extended duration) | 612.42 [64] | 2.76 [67] | 1.00 |
| Bupropion | 175.78 [64] | 1.60 [68] | 1.00 |
| Behavioural interventions | |||
| Specialist behavioural support: one‐to‐one | 465.00 [62] | 1.40 [9] | 2.00 |
| Specialist behavioural support: group‐based | 41.90 [62] | 2.00 [9] | 1.00 |
| Telephone support: proactive | 119 [62] | 1.40 [69] | 0.50 |
| SMS text messaging | 23.68 | 1.71 [61] | 0.50 |
| Printed self‐help materials | 1.21 [6] | 1.19 [70] | 1.00 |
For top‐level interventions, effect is relative increase in the percentage of smokers making a quit attempt in the next 12 months. For pharmaceutical and behavioural interventions effect is relative effect of a quit attempt to be successful versus an unassisted quit rate;
reach was taken from England data;
costs are equated to England data. NRT = nicotine replacement therapy; SMS = short message service.
Costs, QALYs and ICERs per 1000 smokers comparing alternative package versus current package.
| Horizon | Average total costs (€ per 1000 smokers) | Average QALYs (per 1000 smokers) | Incremental cost‐effectiveness ratio (€ per QALY gain) | |
|---|---|---|---|---|
| Current package | 2 years | 1 468 783.00 | 1611.13 | – |
| 5 years | 3 507 385.08 | 3877.85 | – | |
| 10 years | 6 612 182.46 | 7260.26 | – | |
| Life‐time | 18 301 798.23 | 20 953.69 | – | |
| Alternative package | 2 years | 1 468 729.32 | 1611.13 | Dominant |
| 5 years | 3 507 241.88 | 3877.86 | Dominant | |
| 10 years | 6 611 913.37 | 7260.29 | Dominant | |
| Life‐time | 18 301 195.32 | 20 953.83 | Dominant |
ICER = ; incremental cost‐effectiveness ratio; QALYs = quality‐adjusted life years.
Sensitivity analysis: intervention costs per smoker, RRs and reach for life‐time horizon.
| Range | Average total costs (€ per 1000 smokers) | Average QALYs (per 1000 smokers) | Incremental cost‐effectiveness ratio (€ per QALY gain) | |
|---|---|---|---|---|
| Current package | – | 18 301 798.23 | 20 953.69 | – |
| Base case (alternative package) | 18 301 195.32 | 20 953.83 | Dominant | |
| Intervention costs per smoker (€) | 0.22 | 18 301 185.11 | 20 953.83 | Dominant |
| 7.70 | 18 301 215.78 | 20 953.83 | Dominant | |
| Relative risk | 1.18 | 18 301 536.79 | 20 953.75 | Dominant |
| 1.65 | 18 300 790.39 | 20953.93 | Dominant | |
| Reach (%) | 0.20 | 18 301 499.72 | 20 953.76 | Dominant |
| 0.81 | 18 300 604.17 | 20 953.97 | Dominant |
RR = relative risk; QALY = quality‐adjusted life years.